Zoldonrasib plus chemotherapy produces 82% objective response rate in untreated KRAS G12D metastatic pancreatic cancer

The Dana-Farber-led multicenter study paired the KRAS G12D inhibitor zoldonrasib with either modified FOLFIRINOX or gemcitabine/nab-paclitaxel. Objective responses reached 82% and 61% respectively, while ctDNA clearance exceeded 47% in both arms. These rates substantially exceed historical benchmarks for chemotherapy alone, where response rates hover near 30%. The absence of new toxicities suggests the targeted agent can be layered onto existing regimens without additive harm.

Pancreatic cancer's 3% five-year survival for metastatic disease has persisted because KRAS mutations were long considered undruggable. Zoldonrasib belongs to the post-sotorasib wave of allele-specific inhibitors now entering trials. The ctDNA molecular responses observed here mirror patterns seen with KRAS G12C agents in lung cancer, hinting at a class effect on early pharmacodynamic activity that may predict later survival gains.

Original coverage understated the need for randomized data. Single-arm phase I/II results cannot isolate zoldonrasib's contribution from chemotherapy effects or selection bias toward fitter patients. A phase III trial powered for overall survival is required to confirm clinical benefit and to test whether ctDNA clearance serves as a valid surrogate endpoint.

Next steps include dose optimization and biomarker refinement to identify patients most likely to achieve deep molecular responses. Extension cohorts exploring maintenance strategies after induction will clarify durability.